<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37749230</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>29</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>03</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Sep</Month><Day>25</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Association between endothelin-1 and systemic lupus erythematosus: insights from a case-control study.</ArticleTitle><Pagination><StartPage>15970</StartPage><MedlinePgn>15970</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">15970</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-023-43350-0</ELocationID><Abstract><AbstractText>Systemic lupus erythematosus (SLE) is a chronic rheumatic disorder. Endothelin-1, a vasoconstrictor, belongs to the endothelin family and is associated with vascular-related damages. To date, association between ET-1 and pathogenesis of SLE remains unclear. This case-control study was carried out by 314 SLE, 252 non-SLE diseases patients and 500 healthy controls. Serum ET-1, CCN3, IL-28B levels were detected by ELISA, and ET-1 gene polymorphisms (rs5369, rs5370, rs1476046, rs2070699, rs2071942, rs2071943, rs3087459, rs4145451, rs6458155, rs9369217) were genotyped with Kompetitive Allele-Specific PCR. SLE patients had high levels of ET-1, which were correlated with some clinical, laboratory features. Serum CCN3, IL-28B levels were higher in SLE patients, and ET-1 levels were positively correlated with the two cytokines. Rs5370, rs1476046, rs2070699, rs2071942, rs2071943, rs3087459, rs6458155 and rs2070699 were associated with SLE risk. Rs2070699 (T, TT) was related to SLE patients with alopecia. Rs5370 (T, TT, TG), rs1476046 (G,GA), rs2071942 (G,GA) and rs2071943 (G,GA) were associated with SLE patients with pericarditis, pyuria and fever manifestation, respectively. Rs3087459 (CC) and rs9369217 (TC) were related to SLE patients with positive anti-SSB antibody. Rs5369 (AA) was associated with IgG and CRP levels in SLE patients. In conclusion, elevated serum ET-1 in SLE patients may be a potential disease marker, and its gene polymorphisms were related to SLE susceptibility.</AbstractText><CopyrightInformation>&#xa9; 2023. Springer Nature Limited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Rong</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Evidence-Based Medicine, School of Public Health, Southwest Medical University, 1 Xianglin Road, Luzhou, 646000, Sichuan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Chan</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Evidence-Based Medicine, School of Public Health, Southwest Medical University, 1 Xianglin Road, Luzhou, 646000, Sichuan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Yang-Yang</ForeName><Initials>YY</Initials><AffiliationInfo><Affiliation>Department of Evidence-Based Medicine, School of Public Health, Southwest Medical University, 1 Xianglin Road, Luzhou, 646000, Sichuan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Da-Cheng</ForeName><Initials>DC</Initials><AffiliationInfo><Affiliation>Department of Evidence-Based Medicine, School of Public Health, Southwest Medical University, 1 Xianglin Road, Luzhou, 646000, Sichuan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Wang-Dong</ForeName><Initials>WD</Initials><AffiliationInfo><Affiliation>Department of Evidence-Based Medicine, School of Public Health, Southwest Medical University, 1 Xianglin Road, Luzhou, 646000, Sichuan, China. loutch123@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>An-Fang</ForeName><Initials>AF</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, The Affiliated Hospital, Southwest Medical University, 25 Taiping Road, Luzhou, 646000, Sichuan, China. loutch211@163.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>09</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019332">Endothelin-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019332" MajorTopicYN="Y">Endothelin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010493" MajorTopicYN="Y">Pericarditis</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>4</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>9</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>26</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>25</Day><Hour>23</Hour><Minute>27</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37749230</ArticleId><ArticleId IdType="pmc">PMC10520074</ArticleId><ArticleId IdType="doi">10.1038/s41598-023-43350-0</ArticleId><ArticleId IdType="pii">10.1038/s41598-023-43350-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>He N, Leng X, Zeng X. Systemic lupus erythematosus following human papillomavirus vaccination: A case-based review. Int. J. Rheum. Dis. 2022;25:1208&#x2013;1212. doi: 10.1111/1756-185X.14404.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1756-185X.14404</ArticleId><ArticleId IdType="pubmed">35948863</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang C, Li R, Xu WD, Huang AF. Increased levels of sirtuin-1 in systemic lupus erythematosus. Int. J. Rheum. Dis. 2022;25:869&#x2013;876. doi: 10.1111/1756-185X.14360.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1756-185X.14360</ArticleId><ArticleId IdType="pubmed">35644944</ArticleId></ArticleIdList></Reference><Reference><Citation>Ha E, Bae SC, Kim K. Recent advances in understanding the genetic basis of systemic lupus erythematosus. Semin. Immunopathol. 2022;44:29&#x2013;46. doi: 10.1007/s00281-021-00900-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00281-021-00900-w</ArticleId><ArticleId IdType="pubmed">34731289</ArticleId></ArticleIdList></Reference><Reference><Citation>Torres Crigna A, Link B, Samec M, Giordano FA, Kubatka P, Golubnitschaja O. Endothelin-1 axes in the framework of predictive, preventive and personalised (3P) medicine. EPMA J. 2021;12:265&#x2013;305. doi: 10.1007/s13167-021-00248-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13167-021-00248-z</ArticleId><ArticleId IdType="pmc">PMC8334338</ArticleId><ArticleId IdType="pubmed">34367381</ArticleId></ArticleIdList></Reference><Reference><Citation>Kostov K. The causal relationship between endothelin-1 and hypertension: Focusing on endothelial dysfunction, arterial stiffness, vascular remodeling, and blood pressure regulation. Life Basel. 2021;1:986. doi: 10.3390/life11090986.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/life11090986</ArticleId><ArticleId IdType="pmc">PMC8472034</ArticleId><ArticleId IdType="pubmed">34575135</ArticleId></ArticleIdList></Reference><Reference><Citation>Hajialilo M, Tayari P, Ghorbanihaghjo A, Khabbazi A, Malek Mahdavi A, Rashtchizadeh N. Relationship between serum vascular cell adhesion molecule-1 and endothelin-1 levels with organ involvement and disease activity in systemic lupus erythematosus patients. Lupus. 2018;27:1918&#x2013;1925. doi: 10.1177/0961203318796285.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203318796285</ArticleId><ArticleId IdType="pubmed">30157717</ArticleId></ArticleIdList></Reference><Reference><Citation>Alvarez-Cienfuegos A, Cantero-Nieto L, Garc&#xed;a-G&#xf3;mez JA, R&#xed;os-Fern&#xe1;ndez R, Martin J, Gonz&#xe1;lez-Gay MA, et al. Endothelin-1 serum levels in women with rheumatoid arthritis. Acta Reumatol. Port. 2019;44:250&#x2013;257.</Citation><ArticleIdList><ArticleId IdType="pubmed">31575843</ArticleId></ArticleIdList></Reference><Reference><Citation>Borska L, Andrys C, Chmelarova M, Kovarikova H, Krejsek J, Hamakova K, et al. Roles of miR-31 and endothelin-1 in psoriasis vulgaris: Pathophysiological functions and potential biomarkers. Physiol. Res. 2017;66:987&#x2013;992. doi: 10.33549/physiolres.933615.</Citation><ArticleIdList><ArticleId IdType="doi">10.33549/physiolres.933615</ArticleId><ArticleId IdType="pubmed">28937251</ArticleId></ArticleIdList></Reference><Reference><Citation>Stochmal A, Czuwara J, Zaremba M, Rudnicka L. Altered serum level of metabolic and endothelial factors in patients with systemic sclerosis. Arch. Dermatol. Res. 2020;312:453&#x2013;458. doi: 10.1007/s00403-019-01993-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00403-019-01993-y</ArticleId><ArticleId IdType="pmc">PMC7306018</ArticleId><ArticleId IdType="pubmed">31667578</ArticleId></ArticleIdList></Reference><Reference><Citation>Dombrowski Y, O'Hagan T, Dittmer M, Penalva R, Mayoral SR, Bankhead P, et al. Regulatory T cells promote myelin regeneration in the central nervous system. Nat. Neurosci. 2017;20:674&#x2013;680. doi: 10.1038/nn.4528.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4528</ArticleId><ArticleId IdType="pmc">PMC5409501</ArticleId><ArticleId IdType="pubmed">28288125</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin CG, Leu SJ, Chen N, Tebeau CM, Lin SX, Yeung CY, et al. CCN3 (NOV) is a novel angiogenic regulator of the CCN protein family. J. Biol. Chem. 2003;278:24200&#x2013;24208. doi: 10.1074/jbc.M302028200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M302028200</ArticleId><ArticleId IdType="pubmed">12695522</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng L, Wei Y, Shao Y, Li Y, Liu N, Duan L. The emerging roles of CCN3 protein in immune-related diseases. Med. Inflamm. 2021;18(2021):5576059.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8356028</ArticleId><ArticleId IdType="pubmed">34393649</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Liu Y, Xie C, Zhu J, Kreska D, Morel L, et al. Deficiency of type I interferon contributes to Sle2-associated component lupus phenotypes. Arthritis Rheum. 2005;52:3063&#x2013;3072. doi: 10.1002/art.21307.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.21307</ArticleId><ArticleId IdType="pubmed">16200585</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin SC, Kuo CC, Tsao JT, Lin LJ. Profiling the expression of interleukin (IL)-28 and IL-28 receptor &#x3b1; in systemic lupus erythematosus patients. Eur. J. Clin. Invest. 2012;42:61&#x2013;69. doi: 10.1111/j.1365-2362.2011.02557.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2362.2011.02557.x</ArticleId><ArticleId IdType="pubmed">21707611</ArticleId></ArticleIdList></Reference><Reference><Citation>Amezcua-Guerra LM, M&#xe1;rquez-Velasco R, Ch&#xe1;vez-Rueda AK, Castillo-Mart&#xed;nez D, Mass&#xf3; F, P&#xe1;ez A, et al. Type III interferons in systemic lupus erythematosus: Association between interferon &#x3bb;3, disease activity, and anti-Ro/SSA antibodies. J. Clin. Rheumatol. 2017;23:368&#x2013;375. doi: 10.1097/RHU.0000000000000581.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/RHU.0000000000000581</ArticleId><ArticleId IdType="pubmed">28937472</ArticleId></ArticleIdList></Reference><Reference><Citation>Ci W, Zhao J, Qi W, Gao N, Qian J, Zhang G, Wang Y, Pan L, Li M. Characteristics and risk factors of severe coronary artery disease in systemic lupus erythematosus: A multicenter, Chinese Rheumatism Date Center database study. Int. J. Rheum. Dis. 2022;25:1186&#x2013;1195. doi: 10.1111/1756-185X.14402.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1756-185X.14402</ArticleId><ArticleId IdType="pubmed">35880514</ArticleId></ArticleIdList></Reference><Reference><Citation>Mostmans Y, Cutolo M, Giddelo C, Decuman S, Melsens K, Declercq H, et al. The role of endothelial cells in the vasculopathy of systemic sclerosis: A systematic review. Autoimmun. Rev. 2017;16:774&#x2013;786. doi: 10.1016/j.autrev.2017.05.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2017.05.024</ArticleId><ArticleId IdType="pubmed">28572048</ArticleId></ArticleIdList></Reference><Reference><Citation>Davenport AP, Maguire JJ. Endothelin. Handb. Exp. Pharmacol. 2006;176:295&#x2013;329. doi: 10.1007/3-540-32967-6_9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/3-540-32967-6_9</ArticleId><ArticleId IdType="pubmed">16999223</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong X, Wang H, Huang S. Endothelin-1 induces interleukin-18 expression in human osteoblasts. Arch. Oral. Biol. 2014;59:289&#x2013;296. doi: 10.1016/j.archoralbio.2013.11.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.archoralbio.2013.11.006</ArticleId><ArticleId IdType="pubmed">24581851</ArticleId></ArticleIdList></Reference><Reference><Citation>Haq A, El-Ramahi K, Al-Dalaan A, Al-Sedairy ST. Serum and synovial fluid concentrations of endothelin-1 in patients with rheumatoid arthritis. J. Med. 1999;30:51&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">10515240</ArticleId></ArticleIdList></Reference><Reference><Citation>Raschi E, Privitera D, Bodio C, Lonati PA, Borghi MO, Ingegnoli F, et al. Scleroderma-specific autoantibodies embedded in immune complexes mediate endothelial damage: An early event in the pathogenesis of systemic sclerosis. Arthritis Res. Ther. 2020;22:265. doi: 10.1186/s13075-020-02360-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-020-02360-3</ArticleId><ArticleId IdType="pmc">PMC7654597</ArticleId><ArticleId IdType="pubmed">33168071</ArticleId></ArticleIdList></Reference><Reference><Citation>Saleh MA, De Miguel C, Stevens DI, Carmines PK, Pollock DM, Pollock JS. Free radical scavenging decreases endothelin-1 excretion and glomerular albumin permeability during type 1 diabetes. Physiol. Rep. 2016;4:e13055. doi: 10.14814/phy2.13055.</Citation><ArticleIdList><ArticleId IdType="doi">10.14814/phy2.13055</ArticleId><ArticleId IdType="pmc">PMC5210388</ArticleId><ArticleId IdType="pubmed">28039404</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuryliszyn-Moskal A, Klimiuk PA, Ciolkiewicz M, Sierakowski S. Clinical significance of selected endothelial activation markers in patients with systemic lupus erythematosus. J. Rheumatol. 2008;35:1307&#x2013;1313.</Citation><ArticleIdList><ArticleId IdType="pubmed">18484695</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshio T, Masuyama J, Mimori A, Takeda A, Minota S, Kano S. Endothelin-1 release from cultured endothelial cells induced by sera from patients with systemic lupus erythematosus. Ann. Rheum. Dis. 1995;54:361&#x2013;365. doi: 10.1136/ard.54.5.361.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.54.5.361</ArticleId><ArticleId IdType="pmc">PMC1005595</ArticleId><ArticleId IdType="pubmed">7794041</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhaun N, Lilitkarntakul P, Macintyre IM, Muilwijk E, Johnston NR, Kluth DC, et al. Urinary endothelin-1 in chronic kidney disease and as a marker of disease activity in lupus nephritis. Am. J. Physiol. Renal. Physiol. 2009;296:F1477&#x2013;F1483. doi: 10.1152/ajprenal.90713.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajprenal.90713.2008</ArticleId><ArticleId IdType="pmc">PMC2692450</ArticleId><ArticleId IdType="pubmed">19279127</ArticleId></ArticleIdList></Reference><Reference><Citation>Leask A. The role of endothelin-1 signaling in the fibrosis observed in systemic sclerosis. Pharmacol. Res. 2011;63:502&#x2013;503. doi: 10.1016/j.phrs.2011.01.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2011.01.011</ArticleId><ArticleId IdType="pubmed">21315153</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivera-Gonzalez O, Case CT, Wilson NA, Speed JS, Taylor EB. Endothelin receptor antagonism improves glucose tolerance and adipose tissue inflammation in an experimental model of systemic lupus erythematosus. Am. J. Physiol. Endocrinol. Metab. 2023;324:E73&#x2013;E84. doi: 10.1152/ajpendo.00274.2022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpendo.00274.2022</ArticleId><ArticleId IdType="pmc">PMC9870584</ArticleId><ArticleId IdType="pubmed">36476039</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka K, Yoshioka K, Tatsumi K, Kimura S, Kasuya Y. Endothelin regulates function of IL-17-producing T cell subset. Life Sci. 2014;118:244&#x2013;247. doi: 10.1016/j.lfs.2014.01.084.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2014.01.084</ArticleId><ArticleId IdType="pubmed">24530289</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei Y, Peng L, Li Y, Zhang N, Shang K, Duan L, et al. Higher Serum CCN3 is associated with disease activity and inflammatory markers in rheumatoid arthritis. J. Immunol. Res. 2020;9(2020):3891425.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7232667</ArticleId><ArticleId IdType="pubmed">32455138</ArticleId></ArticleIdList></Reference><Reference><Citation>Henrot P, Pain C, Ta&#xef;eb A, Truchetet ME, Cario M. Dysregulation of CCN3 (NOV) expression in the epidermis of systemic sclerosis patients with pigmentary changes. Pigment Cell Melanoma Res. 2020;33:895&#x2013;898. doi: 10.1111/pcmr.12912.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/pcmr.12912</ArticleId><ArticleId IdType="pubmed">32633087</ArticleId></ArticleIdList></Reference><Reference><Citation>Naughton M, Moffat J, Eleftheriadis G, de la Vega GN, Young A, Falconer J, et al. CCN3 is dynamically regulated by treatment and disease state in multiple sclerosis. J. Neuroinflamm. 2020;17:349. doi: 10.1186/s12974-020-02025-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-020-02025-7</ArticleId><ArticleId IdType="pmc">PMC7681974</ArticleId><ArticleId IdType="pubmed">33222687</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang X, Ni B, Mao Z, Xi Y, Chu X, Zhang R, et al. NOV/CCN3 induces cartilage protection by inhibiting PI3K/AKT/mTOR pathway. J. Cell Mol. Med. 2019;23:7525&#x2013;7534. doi: 10.1111/jcmm.14621.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcmm.14621</ArticleId><ArticleId IdType="pmc">PMC6815824</ArticleId><ArticleId IdType="pubmed">31454155</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Z, Natesan V, Shi H, Hamik A, Kawanami D, Hao C, et al. A novel role of CCN3 in regulating endothelial inflammation. J. Cell Commun. Signal. 2010;4:141&#x2013;153. doi: 10.1007/s12079-010-0095-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12079-010-0095-x</ArticleId><ArticleId IdType="pmc">PMC2948121</ArticleId><ArticleId IdType="pubmed">21063504</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanemura S, Seki N, Tsujimoto H, Saito S, Kikuchi J, Sugahara K, et al. Role of interferons (IFNs) in the differentiation of T peripheral helper (Tph) cells. Int. Immunol. 2022;34:533&#x2013;544. doi: 10.1093/intimm/dxac032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/intimm/dxac032</ArticleId><ArticleId IdType="pubmed">35780437</ArticleId></ArticleIdList></Reference><Reference><Citation>Metwally M, Thabet K, Bayoumi A, Nikpour M, Stevens W, Sahhar J, et al. IFNL3 genotype is associated with pulmonary fibrosis in patients with systemic sclerosis. Sci. Rep. 2019;9:14834. doi: 10.1038/s41598-019-50709-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-50709-9</ArticleId><ArticleId IdType="pmc">PMC6795812</ArticleId><ArticleId IdType="pubmed">31619697</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen JY, Wang CM, Chen TD, Jan Wu YJ, Lin JC, Lu LY, et al. Interferon-&#x3bb;3/4 genetic variants and interferon-&#x3bb;3 serum levels are biomarkers of lupus nephritis and disease activity in Taiwanese. Arthritis Res. Ther. 2018;20:193. doi: 10.1186/s13075-018-1683-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-018-1683-z</ArticleId><ArticleId IdType="pmc">PMC6116434</ArticleId><ArticleId IdType="pubmed">30157968</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebrahimi N, Asadikaram G, Mohammadi A, Jahani Y, Moridi M, Masoumi M. The association of endothelin-1 gene polymorphism and its plasma levels with hypertension and coronary atherosclerosis. Arch. Med. Sci. 2019;17:613&#x2013;620. doi: 10.5114/aoms.2019.86770.</Citation><ArticleIdList><ArticleId IdType="doi">10.5114/aoms.2019.86770</ArticleId><ArticleId IdType="pmc">PMC8130481</ArticleId><ArticleId IdType="pubmed">34025830</ArticleId></ArticleIdList></Reference><Reference><Citation>Aydin AF, Vural P, Do&#x11f;ru-Abbaso&#x11f;lu S, &#xc7;il E. The endothelin 1 and endothelin receptor A gene polymorphisms increase the risk of developing papillary thyroid cancer. Mol. Biol. Rep. 2019;46:199&#x2013;205. doi: 10.1007/s11033-018-4461-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11033-018-4461-8</ArticleId><ArticleId IdType="pubmed">30411193</ArticleId></ArticleIdList></Reference><Reference><Citation>Mantaka A, Goulielmos GN, Koulentaki M, Tsagournis O, Voumvouraki A, Kouroumalis EA. Polymorphisms of genes related to endothelial cells are associated with primary biliary cirrhosis patients of Cretan origin. Hum. Immunol. 2012;73:829&#x2013;835. doi: 10.1016/j.humimm.2012.05.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.humimm.2012.05.003</ArticleId><ArticleId IdType="pubmed">22609442</ArticleId></ArticleIdList></Reference><Reference><Citation>Panoulas VF, Douglas KM, Smith JP, Taff&#xe9; P, Stavropoulos-Kalinoglou A, Toms TE, et al. Polymorphisms of the endothelin-1 gene associate with hypertension in patients with rheumatoid arthritis. Endothelium. 2008;15(4):203&#x2013;212. doi: 10.1080/10623320802228708.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10623320802228708</ArticleId><ArticleId IdType="pubmed">18663623</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi S, Chen Q, Xu D, Xie N, Dai Y. Clinical application of protein biomarkers in lupus erythematosus and lupus nephritis. Lupus. 2018;27:1582&#x2013;1590. doi: 10.1177/0961203318773643.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203318773643</ArticleId><ArticleId IdType="pubmed">29720035</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayd&#x131;n AF, Develi-&#x130;&#x15f; S, Do&#x11f;ru-Abbaso&#x11f;lu S, Vural P, Ozderya A, Karada&#x11f; B, et al. Polymorphisms of endothelin 1 (G5665T and T-1370G) and endothelin receptor type A (C+70G and G-231A) in Graves' disease. Int. Immunopharmacol. 2014;18:198&#x2013;202. doi: 10.1016/j.intimp.2013.11.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2013.11.017</ArticleId><ArticleId IdType="pubmed">24291390</ArticleId></ArticleIdList></Reference><Reference><Citation>Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, et al. 2019 European League against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann. Rheum. Dis. 2019;8:1151&#x2013;1159. doi: 10.1136/annrheumdis-2018-214819.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2018-214819</ArticleId><ArticleId IdType="pubmed">31383717</ArticleId></ArticleIdList></Reference><Reference><Citation>Gladman DD, Iba&#xf1;ez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J. Rheumatol. 2002;29:288&#x2013;291.</Citation><ArticleIdList><ArticleId IdType="pubmed">11838846</ArticleId></ArticleIdList></Reference><Reference><Citation>Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, 3rd, et al. 2010 rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann. Rheum. Dis. 2010;69:1580&#x2013;1588. doi: 10.1136/ard.2010.138461.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2010.138461</ArticleId><ArticleId IdType="pubmed">20699241</ArticleId></ArticleIdList></Reference><Reference><Citation>Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthr. Rheum. 1986;29:1039&#x2013;49. doi: 10.1002/art.1780290816.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780290816</ArticleId><ArticleId IdType="pubmed">3741515</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM, et al. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sj&#xf6;gren's syndrome: A consensus and data-driven methodology involving three international patient cohorts. Ann. Rheum Dis. 2017;76:9&#x2013;16. doi: 10.1136/annrheumdis-2016-210571.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2016-210571</ArticleId><ArticleId IdType="pubmed">27789466</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthr. Rheum. 1984;27:361&#x2013;8. doi: 10.1002/art.1780270401.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780270401</ArticleId><ArticleId IdType="pubmed">6231933</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. classification criteria for systemic sclerosis: An American college of rheumatology/European league against rheumatism collaborative initiative. Ann. Rheum. Dis. 2013;72:1747&#x2013;1755. doi: 10.1136/annrheumdis-2013-204424.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2013-204424</ArticleId><ArticleId IdType="pubmed">24092682</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>